Summary of reported patients with myeloid malignancies after HCT for SCD
| Reference . | Total No. . | Conditioning . | Graft status . | No. with myeloid malignancies . | Age at HCT, y . | Myeloid malignancy type . | Duration post-HCT, y . | Outcome . |
|---|---|---|---|---|---|---|---|---|
| Vermylen et al16 | 50 | Myeloablative | Engrafted | 1 | NR | AML | 3 | Refractory leukemiaa |
| Janakiram et al42 | NA | ATG, Flu, Cy, 200 TBI, PT-Cy | Graft failure | 1 | 31 | AML | 0.67 | Deceased |
| Li et al43 | NA | Nonmyeloablative + TBI | Graft failure | 1 | 27 | MDS | 7 | Alive |
| Alzahrani et al7 | 65 | Alem, 300 TBI | Graft failure | 1 | NR | MDS | 3 | Deceased |
| Lawal et al19 | 120 | Alem, 300 to 400 cGy TBI, ± PC, ± PT-Cy | Graft failure | 5 | 20 to 44 | AML × 4 MDS × 1 | 0.33 to 5.5 | Deceased |
| Hsieh et al,44 Jones and DeBaun,17 Goyal et al18 | 47 | Busulfan | HGB-206 Group A | 2 | 25 to 42 | AML × 2 | 3 to 5.5 | Deceased |
| Reference . | Total No. . | Conditioning . | Graft status . | No. with myeloid malignancies . | Age at HCT, y . | Myeloid malignancy type . | Duration post-HCT, y . | Outcome . |
|---|---|---|---|---|---|---|---|---|
| Vermylen et al16 | 50 | Myeloablative | Engrafted | 1 | NR | AML | 3 | Refractory leukemiaa |
| Janakiram et al42 | NA | ATG, Flu, Cy, 200 TBI, PT-Cy | Graft failure | 1 | 31 | AML | 0.67 | Deceased |
| Li et al43 | NA | Nonmyeloablative + TBI | Graft failure | 1 | 27 | MDS | 7 | Alive |
| Alzahrani et al7 | 65 | Alem, 300 TBI | Graft failure | 1 | NR | MDS | 3 | Deceased |
| Lawal et al19 | 120 | Alem, 300 to 400 cGy TBI, ± PC, ± PT-Cy | Graft failure | 5 | 20 to 44 | AML × 4 MDS × 1 | 0.33 to 5.5 | Deceased |
| Hsieh et al,44 Jones and DeBaun,17 Goyal et al18 | 47 | Busulfan | HGB-206 Group A | 2 | 25 to 42 | AML × 2 | 3 to 5.5 | Deceased |
Alem, alemtuzumab; ATG, antithymocyte globulin; cGy, centigray; Cy, cyclophosphamide; Flu, fludarabine; NA, not applicable; NR, not reported; PC, pentostatin/oral cyclophosphamide preconditioning; PT-Cy, posttransplant cyclophosphamide.
As opposed to the other patients who underwent allogeneic HCT and have been reported, this patient developed donor-derived leukemia.